MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Crinetics Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

44.49 5

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

41.85

Massimo

44.6

Metriche Chiave

By Trading Economics

Entrata

-19M

-116M

Vendite

670K

1M

Margine di Profitto

-11,216.004

Dipendenti

437

EBITDA

-19M

-129M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+89.65% upside

Dividendi

By Dow Jones

Utili prossimi

6 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

1.7B

4.3B

Apertura precedente

39.49

Chiusura precedente

44.49

Notizie sul Sentiment di mercato

By Acuity

43%

57%

170 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

7 ott 2025, 16:58 UTC

Utili

BMW Trims 2025 View, Citing Weaker Performance in China

7 ott 2025, 23:43 UTC

Discorsi di Mercato

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7 ott 2025, 23:36 UTC

Discorsi di Mercato

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7 ott 2025, 23:19 UTC

Discorsi di Mercato

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7 ott 2025, 22:50 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

7 ott 2025, 22:50 UTC

Discorsi di Mercato

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7 ott 2025, 22:40 UTC

Discorsi di Mercato

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7 ott 2025, 21:56 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

7 ott 2025, 21:56 UTC

Discorsi di Mercato

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7 ott 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

7 ott 2025, 20:44 UTC

Azioni calde

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7 ott 2025, 19:42 UTC

Discorsi di Mercato

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7 ott 2025, 19:23 UTC

Acquisizioni, Fusioni, Takeovers

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7 ott 2025, 19:07 UTC

Discorsi di Mercato

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7 ott 2025, 19:02 UTC

Discorsi di Mercato

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7 ott 2025, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

7 ott 2025, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

7 ott 2025, 16:20 UTC

Discorsi di Mercato

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7 ott 2025, 16:15 UTC

Discorsi di Mercato

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7 ott 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

7 ott 2025, 15:37 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

7 ott 2025, 15:37 UTC

Discorsi di Mercato

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7 ott 2025, 15:33 UTC

Discorsi di Mercato

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7 ott 2025, 15:25 UTC

Discorsi di Mercato

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7 ott 2025, 15:15 UTC

Discorsi di Mercato

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7 ott 2025, 15:04 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

7 ott 2025, 15:04 UTC

Discorsi di Mercato

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7 ott 2025, 14:56 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

7 ott 2025, 14:56 UTC

Discorsi di Mercato

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7 ott 2025, 14:52 UTC

Utili

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

89.65% in crescita

Previsioni per 12 mesi

Media 80.6 USD  89.65%

Alto 143 USD

Basso 40 USD

Basato su 16 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

16 ratings

15

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

30.39 / 33.46Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Neutral Evidence

Sentiment

By Acuity

170 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat